Trial Profile
A Study to Investigate HCV Response Rates in Real World Patients Traditionally Excluded From Clinical Trials: The HEARTLAND Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HEARTLAND
- 25 Oct 2018 New trial record